Recommended Topic Related To:

Navelbine

"Nov. 7, 2012 -- Statins -- widely prescribed drugs used to help prevent death from heart disease -- may play a role in reducing risk for cancer death, too, a new study shows.

Researchers followed all cancer patients in Denmark diagnos"...

Navelbine

Navelbine

Navelbine Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Navelbine (vinorelbine tartrate) is used to treat non-small cell lung cancer, and is sometimes used in combination with other cancer medications. It is a cancer medication. This medication is available in generic form. Common side effects include nausea, vomiting, fatigue, constipation, diarrhea, dizziness, muscle aches, joint pain, or irritation at the injection site. Temporary hair loss may occur. Normal hair growth should return after treatment has ended.

The usual initial dose of Navelbine when used alone is 30 mg/m2 administered weekly by intravenous injection over 6 to 10 minutes. When used in combination with cisplatin the dose of Navelbine is 100 mg/m2 given every 4 weeks. Navelbine may interact with conivaptan, diclofenac, imatinib, isoniazid, antibiotics, antifungals, antidepressants, heart or blood pressure medications, cancer medicines, or HIV/AIDS medicines. Tell your doctor all medications you use. Navelbine is not recommended for use during pregnancy. It may cause harm to a fetus. Women of childbearing age should use birth control during treatment and for some time afterwards. It is unknown if this drug passes into breast milk. Because of the potential risk to the infant, breast-feeding while using this drug is not recommended.

Our Navelbine (vinorelbine tartrate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Navelbine in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • signs of infection such as fever, chills, flu symptoms, mouth and throat ulcers, rapid heart rate, rapid and shallow breathing, fainting;
  • cough, bronchospasm (wheezing, chest tightness, trouble breathing);
  • severe constipation, stomach pain, bloody or black stools;
  • pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
  • easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
  • numbness, burning, pain, or tingly feeling;
  • problems with vision, hearing, speech, balance, or daily activities;
  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling; or
  • pain, burning, redness, swelling, or skin changes where the IV needle was placed.

Less serious side effects may include:

  • temporary hair loss;
  • jaw pain, joint or muscle pain;
  • tumor pain;
  • weight loss;
  • nausea, vomiting, diarrhea, loss of appetite; or
  • feeling dizzy, weak, or tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Navelbine (Vinorelbine Tartrate) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Navelbine Overview - Patient Information: Side Effects

SIDE EFFECTS: See also Warning section.

Nausea, vomiting, fatigue, constipation, diarrhea, dizziness, muscle aches, joint pain, or irritation at the injection site may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Temporary hair loss may occur. Normal hair growth should return after treatment has ended.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: numbness/tingling/pain in the hands or feet, decreased reflexes, mouth sores, easy bruising/bleeding, weakness, new or increased trouble breathing, cough, severe constipation, stomach/abdominal pain, blood in the urine, mental/mood changes.

Get medical help right away if this rare but very serious side effect occurs: chest pain.

A very serious allergic reaction to this drug is unlikely, but get medical help right away if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Navelbine (Vinorelbine Tartrate)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Navelbine FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following serious adverse reactions, which may include fatalities, are discussed in greater detail in other sections of the label:

Clinical Trials Experience

Because clinical trials are conducted under varying designs and in different patient populations, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.

Single Agent

The data below reflect exposure to NAVELBINE as a single agent administered at a dose of 30 mg/m² on a weekly basis to 365 patients enrolled in 3 controlled studies for metastatic NSCLC and advanced breast cancer. The population included 143 previously untreated metastatic NSCLC patients (Study 3) who received a median of 8 doses of NAVELBINE. The patients were aged 32 to 79 (median 61 years), 71% were male, 91% Caucasian, 48% had adenocarcinoma histology. The data also reflect exposure to NAVELBINE in 222 patients with previously treated advanced breast cancer who received a median of 10 doses of NAVELBINE. NAVELBINE is not indicated for the treatment of breast cancer.

Selected adverse reactions reported in these studies are provided in Tables 1 and 2. The most common adverse reactions ( ≥ 20%) of single agent NAVELBINE were leukopenia, neutropenia, anemia, Aspartate aminotransferase (AST) elevation, nausea, vomiting, constipation, asthenia, injection site reaction, and peripheral neuropathy. The most common ( ≥ 5%) Grade 3 or 4 adverse reactions were neutropenia, leukopenia, anemia, increased total bilirubin, AST elevation, injection site reaction and asthenia. Approximately 49% of NSCLC patients treated with Navelbine experienced at least one dose reduction due to an adverse reaction. Thirteen percent of patients discontinued NAVELBINE due to adverse reactions. The most frequent adverse reactions leading to NAVELBINE discontinuation were asthenia, dyspnea, nausea, constipation, anorexia, myasthenia and fever.

Table 1: Hematologic Adverse Reactions Experienced in > 5% of Patients Receiving NAVELBINE*†

    All patients
(n=365)
NSCLC
(n= 143)
Laboratory Hematologic
Neutropenia < 2,000 cells/mm³ 90% 80%
< 500 cells/mm³ 36% 29%
Leukopenia < 4,000 cells/mm³ 92% 81%
< 1,000 cells/mm³ 15% 12%
Thrombocytopenia < 100,000 cells/mm³ 5% 4%
Anaemia < 11 g/dl 83% 77%
< 8 g/dl 9% 1%
Hospitalizations due to neutropenic complications 9% 8%
*Grade based on modified criteria from the National Cancer Institute version 1.
†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy.

Table 2: Non-hematologic Adverse Reactions Experienced in ≥ 5% of Patients Receiving NAVELBINE*†

  All grades Grades 3+4
All Patients NSCLC All Patients NSCLC
Laboratory
Hepatic
  AST increased (n=346) 67% 54% 6% 3%
  bilirubin increased (n=351) 13% 9% 7% 5%
Clinical
  Nausea 44% 34% 2% 1%
  Asthenia 36% 27% 7% 5%
  Constipation 35% 29% 3% 2%
  Injection site reaction 28% 38% 2% 5%
  Injection site pain 16% 13% 2% 1%
  Neuropathy peripheral} 25% 20% < 2% 1%
  Vomiting 20% 15% 2% 1%
  Diarrhea 17% 13% 1% 1%
  Alopecia 12% 12% <1% 1%
  Phlebitis 7% 10% <1% 1%
  Dyspnea 7% 3% 3% 2%
* Grade based on modified criteria from the National Cancer Institute version 1.
‡ Incidence of paresthesia plus hypesthesia.
†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy.

Myelosuppression: In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 69%, 9% and 1%, respectively of patients receiving single-agent NAVELBINE. Neutropenia is the major dose-limiting toxicity.

Neurotoxicity: neurotoxicity was most commonly manifested as constipation, paresthesia, hypersthesia, and hyporeflexia. Grade 3 and 4 neuropathy was observed in 1% of the patients receiving single-agent NAVELBINE.

Injection site reactions: Injection site reactions, including erythema, pain at injection site, and vein discoloration, occurred in approximately one third of patients; 5% were severe. Phlebitis (chemical phlebitis) along the vein proximal to the site of injection was reported in 10% of patients.

Cardiovascular toxicity: Chest pain occurred in 5% of patients; myocardial infarction occurred in less than 0.1% of patients.

Pulmonary Toxicity and Respiratory Failure: Dyspnea (shortness of breath) was reported in 3% of patients; it was severe in 2%. Interstitial pulmonary changes were documented.

Other: Hemorrhagic cystitis and the syndrome of inappropriate ADH secretion were each reported in < 1% of patients.

In Combination with Cisplatin

Table 3 presents the incidence of selected adverse reactions, occurring in ≥ 10% of NAVELBINE treated patients reported in a randomized trial comparing the combination of NAVELBINE 25 mg/m² administered every week of each 28-day cycle and cisplatin 100 mg/m² administered on day 1 of each 28-day cycle versus cisplatin alone at the same dose and schedule in patients with previously untreated NSCLC (Study 1).

Patients randomized to NAVELBINE plus cisplatin received a median of 3 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. Thirty-Five percent of the eligible patients in the combination arm required treatment discontinuation due to an adverse reaction compared to 19% in the cisplatin alone arm. The incidence of Grade 3 and 4 neutropenia was significantly higher in the NAVELBINE plus cisplatin arm (82%) compared to the cisplatin alone arm (5%). Four patients in the NAVELBINE plus cisplatin arm died of neutropenic sepsis. Seven additional deaths were reported in the combination arm: 2 from cardiac ischemia, 1 cerebrovascular accident, 1 multisystem failure due to an overdose of NAVELBINE, and 3 from febrile neutropenia.

Table 3: Adverse Reactions Experienced by ≥ 10% of Patients on NAVELBINE plus Cisplatin versus Single-Agent Cisplatin*

Laboratory NAVELBINE 25mg/m² plus Cisplatin 100 mg/m² (n=212) Cisplatin 100mg/m² (n=210)
All Grades Grades 3+4 All Grades Grades 3+4
Hematologic
  Neutropenia 89% 82% 26% 5%
  Anemia  89% 24% 72% < 8%
  Leukopenia 88% 58% 31% < 1%
  Thrombocytopenia 29% 5% 21% < 2%
  Febrile neutropenia N/A* 11% N/A* 0%
Renal
  Blood creatinine increased 37% 4% 28% < 5%
Clinical
  Malaise/Fatigue/Lethargy 67% 12% 49% 8%
  Vomiting 60% 13% 60% 14%
  Nausea 58% 14% 57% 12%
  Decreased apetite 46% 0% 37% 0%
  Constipation 35% 3% 16% 1%
  Alopecia 34% 0% 14% 0%
  Weight decreased 34% 1% 21% < 1%
  Fever without infection 20% 2% 4% 0%
  Hearing impaired 18% 4% 18% < 4%
  Injection site reaction 17% < 1% 1% 0%
  Diarrhea 17% < 3% 11% < 2%
  Paraesthesia 17% < 1% 10% < 1%
  Taste alterations 17% 0% 15% 0%
  Peripheral numbness 11% 2% 7% < 1%
  Myalgia/Arthralgia 12% < 1% 3% < 1%
  Phlebitis/Thrombosis/Embolism 10% 3% <1% < 1%
  Weakness 12% < 3% 7% 2%
  Infection 11% < 6% <1% < 1%
  Respiratory tract infection 10% < 5% 3% 3%
*Graded according to the standard SWOG criteria version 1.
*Categorical toxicity grade not specified

Table 4 presents the incidence of selected adverse reactions, occurring in ≥ 10% of NAVELBINE treated patients reported in a randomized trial of NAVELBINE plus cisplatin, vindesine plus cisplatin and NAVELBINE alone in patients with stage III or IV NSCLC who had not received prior chemotherapy. A total of 604 patients received either NAVELBINE 30 mg/m² every week plus cisplatin 120 mg/m² on Day 1 and Day 29, then every 6 weeks thereafter (N=207), vindesine 3 mg/m² for 6 weeks, then every other week thereafter plus cisplatin 120 mg/m² on Days 1 and Day 29, then every 6 weeks thereafter (N=193) or NAVELBINE 30mg/m² every week (N=204).

Patients randomized to NAVELBINE plus cisplatin received a median of 15 weeks of treatment, vindesine plus cisplatin 12 weeks and NAVELBINE received 13 weeks. Study discontinuation due to an adverse reaction was required in 27, 22 and 10% of the patients randomized to NAVELBINE plus cisplatin, vindesine plus cisplatin and cisplatin alone arms, respectively. Grade 3 and 4 neutropenia was significantly greater in the NAVELBINE plus cisplatin arm (78%) compared to vindesine plus cisplatin (48%) and NAVELBINE alone (53%). Neurotoxicity, including peripheral neuropathy and constipation was reported in 44% (Grades 34, 7%) of the patients receiving NAVELBINE plus cisplatin, 58% (Grades 3-4, 17%) of the patients receiving vindesine and cisplatin and 44% (Grades 3-4, 8.5%) of the patients receiving NAVELBINE alone.

Table 4: Adverse Reactions Experienced by ≥ 10 % of Patients from a Comparative Trial of NAVELBINE Plus Cisplatin versus Vindesine Plus Cisplatin versus Single-Agent NAVELBINE*

  NAVELBINE/ Cisplatinf† Vindesine/ Cisplatin‡ NAVELBINE§
All Grades Grades 3+4 All Grades Grades 3+ 4 All Grades Grades 3+4
Laboratory
Hematologic
  Neutropenia 95% 78% 79% 48% 85% 53%
  Leukopenia 94% 57% 82% 27% 83% 32%
  Thrombocytopenia 15% 4% 10% 3.5% 3% 0%
Renal
  Blood creatinine increased| 46% N/A 37% N/A 13% N/A
Clinical
  Nausea/Vomiting 74% 30% 72% 25% 31% 2%
  Alopecia 51% 7.5% 56% 14% 30% 2%
  Neurotoxicity¶ 44% 7% 58% 17% 44% 8.5%
  Diarrhoea 25% 1.5% 24% 1% 12% 0.5%
  Injection site reaction 17% 2.5% 7% 0% 22% 2%
  Ototoxicity 10% 2% 14% 1% 1% 0%
* Grade based on criteria from the World Health Organization (WHO).
† n=194 to 207; all patients receiving NAVELBINE/ cisplatin with laboratory and non-laboratory data.
‡ n=173 to 192; all patients receiving vindesine/ cisplatin with laboratory and non-laboratory data.
§ n=165 to 201; all patients receiving NAVELBINE with laboratory and non-laboratory data.
Categorical toxicity grade not specified.
¶ Neurotoxicity includes peripheral neuropathy and constipation.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of NAVELBINE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Infections and infestations: pneumonia

Immune system disorders: anaphylactic reaction, pruritus, urticaria, angioedema

Nervous system disorders: loss of deep tendon reflexes, muscular weakness, gait disturbance, headache

Ear and labyrinth disorders: vestibular disorder, hearing impaired

Cardiac disorders: tachycardia

Respiratory disorders: pulmonary edema

Vascular disorders: pulmonary embolism, deep vein thrombosis, hypertension, hypotension, flushing, vasodilatation

Gastrointestinal disorders: mucosal inflammation, dysphagia, pancreatitis

Skin disorders: generalized cutaneous reactions (rash)

Musculoskeletal and connective tissue disorders: jaw pain, myalgia, arthralgia

General disorders and administration site conditions: injection site rash, urticaria, blistering, sloughing of skin

Injury, poisoning and procedural complications: radiation recall phenomenon, dermatitis, esophagitis

Laboratory abnormalities: electrolyte imbalance including hyponatremia

Other: tumor pain, back pain, abdominal pain

Read the entire FDA prescribing information for Navelbine (Vinorelbine Tartrate) »

A A A

Navelbine - User Reviews

Navelbine User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Navelbine sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.

Health Resources
Related Supplements
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations